Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
Its flu shot was being developed for people 50 and older.
- Simplified Text
-
Moderna's flu shot was being developed for people 50 and older
- Confidence Score
- 0.900
- Claim Maker
- The author
- Context Type
- News Article
- Context Details
-
{ "vaccine": "flu shot", "organization": "Moderna", "target_demographic": "people 50 and older" } - Subject Tags
- UUID
- a1164c03-3c67-4e0d-b582-3ee3267fcf8b
- Vector Index
- âś— No vector
- Created
- February 15, 2026 at 4:02 PM (6 months ago)
- Last Updated
- February 15, 2026 at 4:02 PM (6 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
30
claims
🔥
1 week ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.
Similar Claims (5)
Other claims identified as semantically similar to this one.
-
Simplified: Moderna concluded its flu shot was superior to GSK’s product6 months ago
-
Simplified: Moderna is a pioneer in using mRNA technology with the Covid vaccine6 months ago
-
Simplified: Pfizer has been in a race with Moderna to develop an mRNA flu vaccine6 months ago
-
Simplified: The FDA notified Moderna that the agency would not review its mRNA flu vaccine6 months ago
-
Simplified: Moderna has been harder hit than other vaccine developers as federal health officials have turned against mRNA technology and some vaccines6 months ago